ATE423551T1 - Eine missbrauch verhinderende, transdermale dosierungsform, die einen wirkstoff und einen antagonisten des wirkstoffs enthält - Google Patents

Eine missbrauch verhinderende, transdermale dosierungsform, die einen wirkstoff und einen antagonisten des wirkstoffs enthält

Info

Publication number
ATE423551T1
ATE423551T1 AT04760495T AT04760495T ATE423551T1 AT E423551 T1 ATE423551 T1 AT E423551T1 AT 04760495 T AT04760495 T AT 04760495T AT 04760495 T AT04760495 T AT 04760495T AT E423551 T1 ATE423551 T1 AT E423551T1
Authority
AT
Austria
Prior art keywords
active ingredient
dosage form
agent component
adverse
abuse
Prior art date
Application number
AT04760495T
Other languages
German (de)
English (en)
Inventor
John R Hart
Steven C Anderson
Melissa A Vanblaricom
Ellen R Bosl
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Application granted granted Critical
Publication of ATE423551T1 publication Critical patent/ATE423551T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04760495T 2003-04-30 2004-03-23 Eine missbrauch verhinderende, transdermale dosierungsform, die einen wirkstoff und einen antagonisten des wirkstoffs enthält ATE423551T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46724303P 2003-04-30 2003-04-30
US10/744,966 US20040219195A1 (en) 2003-04-30 2003-12-23 Abuse-resistant transdermal dosage form

Publications (1)

Publication Number Publication Date
ATE423551T1 true ATE423551T1 (de) 2009-03-15

Family

ID=33313652

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04760495T ATE423551T1 (de) 2003-04-30 2004-03-23 Eine missbrauch verhinderende, transdermale dosierungsform, die einen wirkstoff und einen antagonisten des wirkstoffs enthält

Country Status (9)

Country Link
US (2) US20040219195A1 (cg-RX-API-DMAC7.html)
EP (1) EP1651196B1 (cg-RX-API-DMAC7.html)
JP (2) JP2006525315A (cg-RX-API-DMAC7.html)
AT (1) ATE423551T1 (cg-RX-API-DMAC7.html)
AU (2) AU2004237579A1 (cg-RX-API-DMAC7.html)
CA (1) CA2523709A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004019653D1 (cg-RX-API-DMAC7.html)
ES (1) ES2322154T3 (cg-RX-API-DMAC7.html)
WO (1) WO2004098568A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0409945A (pt) 2003-04-30 2006-04-25 Purdue Pharma Lp forma de dosagem resistente à alteração
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
CA2611224C (en) * 2005-06-10 2014-01-21 3M Innovative Properties Company Method for handling adhesive laminate sections
US9522188B2 (en) * 2005-12-13 2016-12-20 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
US7740879B2 (en) * 2006-01-17 2010-06-22 Harrogate Holdings Abuse resistant transdermal drug delivery patch
DE102006025282A1 (de) * 2006-05-31 2007-12-20 Lts Lohmann Therapie-Systeme Ag Selbstzerstörendes transdermales therapeutisches System
ES2577390T3 (es) 2006-07-21 2016-07-14 Biodelivery Sciences International, Inc. Dispositivos de administración transmucosa con mayor captación
US20080140024A1 (en) * 2006-12-08 2008-06-12 Yoseph Yaacobi Drug delivery device
US9700552B2 (en) * 2008-02-28 2017-07-11 Syntropharma Limited Pharmaceutical compositions for treatment of addiction
JP5386205B2 (ja) * 2009-03-19 2014-01-15 リンテック株式会社 経皮吸収型貼付剤
JP2013524275A (ja) * 2010-04-03 2013-06-17 ドシ，プラフル 薬剤を含む医療機器、その製造方法とその使用方法
MX352959B (es) 2011-08-18 2017-12-15 Biodelivery Sciences Int Inc Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
WO2013148506A1 (en) * 2012-03-30 2013-10-03 3M Innovative Properties Company Urea-based and urethane-based pressure sensitive adhesive blends
US9950106B2 (en) 2012-12-05 2018-04-24 Cook Medical Technologies Llc Antimicrobial barrier device
RS58759B1 (sr) * 2014-01-22 2019-06-28 4P Therapeutics Transdermalni sistemi koji onemogućavaju zloupotrebu i pogrešnu upotrebu
WO2016099986A2 (en) 2014-12-18 2016-06-23 3M Innovative Properties Company Methods of handling adhesive laminate patches
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
EP3247262A1 (en) * 2015-01-23 2017-11-29 Marcio Marc Abreu Apparatus and method for skin treatment
CN110470607B (zh) * 2018-05-09 2021-12-07 江苏集萃智能液晶科技有限公司 一种检测混合溶液中亲水性有机溶剂含量的方法
WO2020008370A1 (en) * 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal patch

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1602344A (en) * 1924-01-09 1926-10-05 Eagle Peter Medicating compress
US2807262A (en) * 1952-12-10 1957-09-24 Robert B Lew Perforated plastic adhesive tape bandage
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4539256A (en) * 1982-09-09 1985-09-03 Minnesota Mining And Manufacturing Co. Microporous sheet material, method of making and articles made therewith
US4693776A (en) * 1985-05-16 1987-09-15 Minnesota Mining And Manufacturing Company Macromer reinforced pressure sensitive skin adhesive
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
US4743249A (en) * 1986-02-14 1988-05-10 Ciba-Geigy Corp. Dermal and transdermal patches having a discontinuous pattern adhesive layer
DE3634016A1 (de) * 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US4917688A (en) * 1987-01-14 1990-04-17 Nelson Research & Development Co. Bandage for transdermal delivery of systemically-active drug
JPH0538010Y2 (cg-RX-API-DMAC7.html) * 1987-03-17 1993-09-27
KR970008118B1 (ko) * 1987-07-09 1997-05-21 엘테에스 로오만 테라피-지스테메 게엠베하 운트 콤파니 카게 피부 침투성 치료 시스템
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5176917A (en) * 1989-03-15 1993-01-05 Lts Lohmann Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5756117A (en) * 1992-04-08 1998-05-26 International Medical Asscociates, Inc. Multidose transdermal drug delivery system
CA2173855C (en) * 1993-10-29 2007-06-26 Mieczyslaw H. Mazurek Pressure-sensitive adhesives having microstructured surfaces
US5494680A (en) * 1993-12-08 1996-02-27 Minnesota Mining And Manufacturing Company Transdermal delivery device
WO1997004835A1 (de) * 1995-07-28 1997-02-13 Novartis Ag Transdermales system
US5840327A (en) * 1995-08-21 1998-11-24 Alza Corporation Transdermal drug delivery device having enhanced adhesion
US5985317A (en) * 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US20020110585A1 (en) * 1999-11-30 2002-08-15 Godbey Kristin J. Patch therapeutic agent delivery device having texturized backing
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
KR100904158B1 (ko) * 2001-03-16 2009-06-23 알자 코포레이션 펜타닐 투여용 경피성 패치
DK2316439T3 (en) * 2001-05-01 2015-08-10 Euro Celtique Sa Abuse-proof transdermal systems containing opioids
CA2496454A1 (en) * 2002-04-23 2003-11-06 Alza Corporation Transdermal analgesic systems with reduced abuse potential
ES2323127T3 (es) * 2002-08-20 2009-07-07 Euro-Celtique S.A. Forma posologica transdermica que comprende un agente activo y una forma de sal y una forma de base libre de un antagonista.
US20040109886A1 (en) * 2002-08-27 2004-06-10 Larry Rigby Methods and apparatus for transdermal delivery of abusable drugs with a deterrent agent
US20040191301A1 (en) * 2003-03-27 2004-09-30 Van Duren Albert Philip Transdermal device having a phase change material
BRPI0409945A (pt) * 2003-04-30 2006-04-25 Purdue Pharma Lp forma de dosagem resistente à alteração
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
DE102004038179A1 (de) * 2004-08-06 2006-03-16 Daimlerchrysler Ag Verfahren zur Herstellung einer thermisch beschichteten Zylinderlauffläche mit einer Einfuhrfase

Also Published As

Publication number Publication date
AU2010257440B2 (en) 2011-11-24
WO2004098568A2 (en) 2004-11-18
EP1651196A2 (en) 2006-05-03
ES2322154T3 (es) 2009-06-17
DE602004019653D1 (de) 2009-04-09
AU2004237579A1 (en) 2004-11-18
WO2004098568A3 (en) 2005-02-03
US20040219195A1 (en) 2004-11-04
US20100068249A1 (en) 2010-03-18
EP1651196B1 (en) 2009-02-25
AU2010257440A1 (en) 2011-01-20
CA2523709A1 (en) 2004-11-18
JP2012140453A (ja) 2012-07-26
JP2006525315A (ja) 2006-11-09

Similar Documents

Publication Publication Date Title
DE602004019653D1 (de) Eine Missbrauch verhinderende, transdermale Dosierungsform, die einen Wirkstoff und einen Antagonisten des Wirkstoffs enthält
CY1109070T1 (el) Διαδερμικη μορφη δοσολογιας περιλαμβανουσα ενα δραστικο παραγοντα και ενα αλας και μια μορφη ελευθερης βασεως ενος ανταγωνιστη
DE60143360D1 (de) Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
EA200501702A1 (ru) Устойчивая к манипуляциям дозировочная форма для трансдермального введения
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
DK1526839T3 (da) Orale farmaceutiske former for flydende lægemidler med forbedret biotilgængelighed
DE69532751D1 (de) Kosmetische, pharmazeutische oder dermatologische Zusammensetzung, sowie die Zusammensetzung Alpha-TNFAntagonisten enthaltend
IS6557A (is) Blandaðar sjúkdómsmeðferðir úr blóðþrýstingslækkandi efnum og efnum sem hamla æðamyndun
DE60318013D1 (de) N-oxid von n-phenyl-2-pyrimidinaminderivaten
DK1178783T3 (da) Indretning og anvendelse til forögelse af den transdermale permeation af lægemidler
EA200400689A1 (ru) Фармацевтические и косметические композиции, содержащие ароматические альдегиды, содержащие оксигруппу
HUP9802971A1 (hu) Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
CY1106319T1 (el) Τοπικη θepαπεια στη μασταλγια
BR0311903A (pt) Tratamento para depressão e ansiedade pela combinação de um inibidor de pde iv e um agente antidepressivo ou ansiolìtico
NO20073575L (no) Farmasoytiske sammensetninger for behandling av cellulitt
DE69909747D1 (de) Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen
CA2494473A1 (en) Stabilized protein compositions for topical administration and methods of making same
AR038858A1 (es) Combinacion
SE0103276D0 (sv) Anordning för administrering av salva till en hudyta
Cao et al. Efficacy of a topical proteinase-activated receptor-2 inhibitor on cowhage-induced pruritus: a randomized placebo-controlled double-blind study.
DE60135390D1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
ATE487492T1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
DE50210037D1 (de) VERWENDUNG VON WIRKSTOFFEN MIT õ-OPIOID-REZEPTOR AGONISTISCHER WIRKUNG UND OPIOID-REZEPTOR ANTAGONISTISCHER WIRKUNG ALS KOMBINATIONSARZNEIMITTEL ZUR KREBSBEHANDLUNG

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties